These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
262 related articles for article (PubMed ID: 31629760)
1. Boosting immune system against cancer by melatonin: A mechanistic viewpoint. Mortezaee K; Potes Y; Mirtavoos-Mahyari H; Motevaseli E; Shabeeb D; Musa AE; Najafi M; Farhood B Life Sci; 2019 Dec; 238():116960. PubMed ID: 31629760 [TBL] [Abstract][Full Text] [Related]
2. Resveratrol for targeting the tumor microenvironment and its interactions with cancer cells. Mu Q; Najafi M Int Immunopharmacol; 2021 Sep; 98():107895. PubMed ID: 34171623 [TBL] [Abstract][Full Text] [Related]
5. Metabolic Regulation of Tregs in Cancer: Opportunities for Immunotherapy. Wang H; Franco F; Ho PC Trends Cancer; 2017 Aug; 3(8):583-592. PubMed ID: 28780935 [TBL] [Abstract][Full Text] [Related]
6. Role of heterogeneous regulatory T cells in the tumor microenvironment. Wei T; Zhong W; Li Q Pharmacol Res; 2020 Mar; 153():104659. PubMed ID: 31982490 [TBL] [Abstract][Full Text] [Related]
7. Anti-cancer Therapies Employing IL-2 Cytokine Tumor Targeting: Contribution of Innate, Adaptive and Immunosuppressive Cells in the Anti-tumor Efficacy. Mortara L; Balza E; Bruno A; Poggi A; Orecchia P; Carnemolla B Front Immunol; 2018; 9():2905. PubMed ID: 30619269 [TBL] [Abstract][Full Text] [Related]
8. Modulation of the tumor microenvironment (TME) by melatonin. Mu Q; Najafi M Eur J Pharmacol; 2021 Sep; 907():174365. PubMed ID: 34302814 [TBL] [Abstract][Full Text] [Related]
9. Adoptive immunotherapy combined with FP treatment for head and neck cancer: An in vitro study. Nishio-Nagai M; Suzuki S; Yoshikawa K; Ueda R; Kazaoka Y Int J Oncol; 2017 Nov; 51(5):1471-1481. PubMed ID: 29048671 [TBL] [Abstract][Full Text] [Related]
10. Modulation of apoptosis by melatonin for improving cancer treatment efficiency: An updated review. Mortezaee K; Najafi M; Farhood B; Ahmadi A; Potes Y; Shabeeb D; Musa AE Life Sci; 2019 Jul; 228():228-241. PubMed ID: 31077716 [TBL] [Abstract][Full Text] [Related]
11. Chemoresistance in mesenchymal lung cancer cells is correlated to high regulatory T cell presence in the tumor microenvironment. Zhang LN; Xin T; Chen M; Gao P IUBMB Life; 2019 Jul; 71(7):986-991. PubMed ID: 31066485 [TBL] [Abstract][Full Text] [Related]
12. Acquired resistance to cancer immunotherapy: Role of tumor-mediated immunosuppression. Saleh R; Elkord E Semin Cancer Biol; 2020 Oct; 65():13-27. PubMed ID: 31362073 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of Nr4a Receptors Enhances Antitumor Immunity by Breaking Treg-Mediated Immune Tolerance. Hibino S; Chikuma S; Kondo T; Ito M; Nakatsukasa H; Omata-Mise S; Yoshimura A Cancer Res; 2018 Jun; 78(11):3027-3040. PubMed ID: 29559474 [TBL] [Abstract][Full Text] [Related]
14. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells. Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085 [TBL] [Abstract][Full Text] [Related]
15. Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity. Chen ML; Yan BS; Lu WC; Chen MH; Yu SL; Yang PC; Cheng AL Int J Cancer; 2014 Jan; 134(2):319-31. PubMed ID: 23818246 [TBL] [Abstract][Full Text] [Related]
16. Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells. Sasidharan Nair V; Elkord E Immunol Cell Biol; 2018 Jan; 96(1):21-33. PubMed ID: 29359507 [TBL] [Abstract][Full Text] [Related]
17. The function and potential drug targets of tumour-associated Tregs for cancer immunotherapy. Yan S; Zhang Y; Sun B Sci China Life Sci; 2019 Feb; 62(2):179-186. PubMed ID: 30610537 [TBL] [Abstract][Full Text] [Related]
18. HLA-DR in Cytotoxic T Lymphocytes Predicts Breast Cancer Patients' Response to Neoadjuvant Chemotherapy. Saraiva DP; Jacinto A; Borralho P; Braga S; Cabral MG Front Immunol; 2018; 9():2605. PubMed ID: 30555458 [TBL] [Abstract][Full Text] [Related]
19. Roles of regulatory T cells in cancer immunity. Takeuchi Y; Nishikawa H Int Immunol; 2016 Aug; 28(8):401-9. PubMed ID: 27160722 [TBL] [Abstract][Full Text] [Related]
20. Optimizing TNFR2 antagonism for immunotherapy with tumor microenvironment specificity. Yang M; Tran L; Torrey H; Song Y; Perkins H; Case K; Zheng H; Takahashi H; Kuhtreiber WM; Faustman DL J Leukoc Biol; 2020 Jun; 107(6):971-980. PubMed ID: 32202358 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]